A compendium of studies has unveiled c-MET’s ability to upregulate programmed cell death-ligand 1 (PD-L1) in diverse cancers, including liver cancer, potentially offering the tantalizing prospect of simultaneous inhibition of c-MET and PD-L1 with c-MET inhibitors (6–8). Here, MET is linked to liver cancer.